Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Healthcare Medical Devices
Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers... see more

TSXV:EVMT - Post Discussion

Evome Medical Technologies Inc > The Future looks very Friendly boys!
View:
Post by ANALOG GUY on Apr 05, 2024 5:10pm

The Future looks very Friendly boys!

Evome Medical Technologies has a 360% upside, Leede says

A new development at Evome Medical Technologies (Evome Medical Technologies Stock Quote, Chart, News, Analysts, Financials TSXV:EVMT) has Leede Jones Gable analyst Greg McLeish maintaining his bullish stance on the stock.
In a research update to clients April 4, McLeish maintained his “Buy” rating and price target of $1.15 on EVMT, implying a return of 360% at the time of publication.

The analyst thinks Evome will post EBITDA of $852,000 on revenue of $62.6-million in fiscal 2023. He expects those numbers will be EBITDA of $2.01-million on a topline of $62.2-million in fiscal 2024

Be the first to comment on this post
Evome Medical Technologies Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities